Skylands Capital LLC Has $8.69 Million Stock Holdings in Bristol Myers Squibb Company (NYSE:BMY)

Skylands Capital LLC lowered its position in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 13.0% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 142,450 shares of the biopharmaceutical company's stock after selling 21,225 shares during the quarter. Bristol Myers Squibb accounts for about 1.3% of Skylands Capital LLC's holdings, making the stock its 23rd largest position. Skylands Capital LLC's holdings in Bristol Myers Squibb were worth $8,688,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of the company. Pinney & Scofield Inc. acquired a new position in shares of Bristol Myers Squibb in the 4th quarter valued at $25,000. Park Square Financial Group LLC bought a new stake in Bristol Myers Squibb in the fourth quarter valued at about $26,000. Fairway Wealth LLC acquired a new position in Bristol Myers Squibb in the fourth quarter worth about $28,000. Transce3nd LLC bought a new position in Bristol Myers Squibb during the fourth quarter worth about $28,000. Finally, Global Wealth Strategies & Associates boosted its holdings in Bristol Myers Squibb by 137.5% during the first quarter. Global Wealth Strategies & Associates now owns 475 shares of the biopharmaceutical company's stock valued at $29,000 after purchasing an additional 275 shares in the last quarter. Institutional investors and hedge funds own 76.41% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on BMY. UBS Group decreased their price target on Bristol Myers Squibb from $60.00 to $54.00 and set a "neutral" rating on the stock in a research note on Friday, April 11th. William Blair reaffirmed a "market perform" rating on shares of Bristol Myers Squibb in a report on Friday, April 25th. Jefferies Financial Group cut their price target on shares of Bristol Myers Squibb from $70.00 to $68.00 and set a "buy" rating for the company in a report on Wednesday, April 23rd. The Goldman Sachs Group reaffirmed a "neutral" rating and set a $55.00 price objective (down from $67.00) on shares of Bristol Myers Squibb in a research note on Tuesday, April 8th. Finally, Piper Sandler started coverage on shares of Bristol Myers Squibb in a research note on Tuesday, April 22nd. They issued an "overweight" rating and a $65.00 target price for the company. Two analysts have rated the stock with a sell rating, thirteen have issued a hold rating, six have given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, Bristol Myers Squibb has a consensus rating of "Hold" and a consensus target price of $58.00.

Insider Activity

In other Bristol Myers Squibb news, EVP Samit Hirawat purchased 4,250 shares of the company's stock in a transaction dated Friday, April 25th. The shares were bought at an average price of $47.58 per share, with a total value of $202,215.00. Following the completion of the transaction, the executive vice president directly owned 83,513 shares in the company, valued at $3,973,548.54. This trade represents a 5.36% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.07% of the stock is owned by company insiders.

Bristol Myers Squibb Trading Up 0.3%

Shares of Bristol Myers Squibb stock traded up $0.13 on Wednesday, hitting $47.64. 12,259,936 shares of the company's stock traded hands, compared to its average volume of 12,912,429. The firm's 50-day moving average price is $47.80 and its two-hundred day moving average price is $53.80. The company has a debt-to-equity ratio of 2.65, a current ratio of 1.28 and a quick ratio of 1.17. The stock has a market capitalization of $96.95 billion, a PE ratio of 17.84, a price-to-earnings-growth ratio of 1.37 and a beta of 0.36. Bristol Myers Squibb Company has a one year low of $39.35 and a one year high of $63.33.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last issued its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.50 by $0.30. The firm had revenue of $11.20 billion for the quarter, compared to analysts' expectations of $10.77 billion. Bristol Myers Squibb had a return on equity of 87.62% and a net margin of 11.38%. The company's revenue was down 5.6% compared to the same quarter last year. During the same quarter last year, the business earned ($4.40) earnings per share. On average, research analysts expect that Bristol Myers Squibb Company will post 6.74 EPS for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, August 1st. Stockholders of record on Thursday, July 3rd will be given a dividend of $0.62 per share. The ex-dividend date of this dividend is Thursday, July 3rd. This represents a $2.48 dividend on an annualized basis and a dividend yield of 5.21%. Bristol Myers Squibb's dividend payout ratio is 92.88%.

Bristol Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.